Oramed Pharmaceuticals Inc. (ORMP)
NASDAQ: ORMP · Real-Time Price · USD
3.570
-0.120 (-3.25%)
Nov 20, 2026, 4:00 PM EST - Market closed
Oramed Pharmaceuticals Market Cap
Oramed Pharmaceuticals has a market cap or net worth of $155.24 million as of November 20, 2026. It is the 21,637th most valuable company in the world and the 3,658th biggest in the United States. Its market cap has increased by 56.34% in one year.
Market Cap
155.24M
Enterprise Value
92.21M
1-Year Change
56.34%
Global Rank
Country Rank
#3,658 United States
Category
ChartMarket Cap Chart
Since May 31, 2007, Oramed Pharmaceuticals's market cap has increased from $29.90M to $155.24M, an increase of 419.21%. That is a compound annual growth rate of 8.82%.
| Date | Market Cap | % Change |
|---|---|---|
| Nov 20, 2026 | 155.20M | 36.86% |
| Dec 31, 2025 | 113.40M | 16.19% |
| Dec 31, 2024 | 97.60M | 4.72% |
| Dec 29, 2023 | 93.20M | -80.20% |
| Dec 30, 2022 | 470.60M | -13.48% |
| Dec 31, 2021 | 543.90M | 441.73% |
| Dec 31, 2020 | 100.40M | 12.05% |
| Dec 31, 2019 | 89.60M | 71.98% |
| Dec 31, 2018 | 52.10M | -59.55% |
| Dec 29, 2017 | 128.80M | 58.62% |
| Dec 30, 2016 | 81.20M | -18.15% |
| Dec 31, 2015 | 99.20M | 115.18% |
| Dec 31, 2014 | 46.10M | -62.40% |
| Dec 31, 2013 | 122.60M | 330.18% |
| Dec 31, 2012 | 28.50M | 45.41% |
| Dec 30, 2011 | 19.60M | 11.36% |
| Dec 31, 2010 | 17.60M | -31.52% |
| Dec 31, 2009 | 25.70M | 16.82% |
| Dec 31, 2008 | 22.00M | 83.33% |
| Dec 31, 2007 | 12.00M | -59.87% |
| May 31, 2007 | 29.90M | - |
View and export this data all the way back to 2007. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Korro Bio | 168.69M |
| Entrada Therapeutics | 158.62M |
| Yarrow Bioscience | 155.23M |
| Palisade Bio | 153.53M |
| InflaRx | 153.26M |
| Eledon Pharmaceuticals | 150.48M |
| Atrium Therapeutics | 149.92M |
| Veraxa Biotech AG | 147.06M |